REFERENCES
Abdel-Wahab YH. Vitamin C supplementation decreases insulin resistance and improves glucose homeostasis in obese hyperglycemic mice. Metabolism 51; 514-517, 2002.

Alberti KGMM. Treating type 2 diabetes-today's targets, tomorrow's goals. Diab Obes Metab 3; S3-S10, 2001.


Bonfigli AR. Vitamin E intake reduces plasminogen activator factor inhibitor type 1 in T2Dm patients. Diabetes Nutritional Metabolism 14; 71-77, 2001.


References


Cunningham JJ. Reduced mononuclear leukocyte ascorbic acid content in adults with insulin-dependent diabetes mellitus consuming adequate dietary vitamin C. Metabolism 40;146-149, 1991.


Eckert M, Schejbal P. Therapy of neuropathies with a vitamin B combination. Symptomatic treatment of painful diseases of the peripheral nervous


Ganz MB, Seftel A. Glucose-induced changes in protein kinase C and nitric oxide are prevented by vitamin E. Am J Physiol 278; E146-E152, 2000.


Howes JB. Effects of dietary supplementation with isoflavones from red clover on ambulatory blood pressure and endothelial function in postmenopausal type 2 diabetes. Diabetes Obesity Metabolism 5; 325-332, 2003.


Hutchinson ML. Effects of glucose and select pharmacologic agents on leukocyte ascorbic acid levels. Feed Proceedings 42; 930, 1983.


Kelly IE, Han TS, Walsh K, Lean ME. Effects of thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diab Care 22; 288-293, 1999.


Ko CH, Shen SC, Chen YC. Hydroxylation at C40 or C6 is essential for apoptosis-inducing activity of flavanone through activation of the caspase-3 cascade and production of reactive oxygen species. Free Rad Biol Med. 36; 897-910, 2004.


Koya D, Jirousek MR, Lin YW, Ishii H, Kuboki K, King GL. Characterization of protein kinase C beta isoform activation on the gene expression of transforming growth factor-beta, extracellular matrix components, and


Luo S, Nemec J, Ning B, Yunnan Zhiwu Yanjiu 17; 89-95, 1995.


McAuliffe AV. Administration of ascorbic acid and an aldose reductase inhibitor (tolrestat) in diabetes: effect on albumin excretion. Metabolism 80; 277-284, 1998.

McCarty MF. High-dose biotin, an inducer of glucokinase expression, may synergize with chromium picolinate to enable a definitive nutritional therapy for type II diabetes. Medical Hypotheses 52; 401-406, 1999.


Michael MD, Kulkarni RN, Postic C, Previs SF, Shulman GI, Magnuson MA, Kahn CR. Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Mol Cell 6; 87-97, 2000.


Mullan BA. Ascorbic acid reduces blood pressure and arterial stiffness in type 2 diabetes. Hypertension 40; 804-809, 2002.


Nathan DM, Meigs J, Singer DE. The epidemiology of cardiovascular disease in type 2 diabetes mellitus: how sweet it is ... or is it? The Lancet 350; S14-S19, 1997.


Sancetta SM, Ayres PR, Scott RW. The use of vitamin B12 in the management of neurological manifestations of diabetic mellitus, with notes on the administration of massive doses. Annal International Medicine 35; 1028-1048, 1951.


Secher K. The bearing of the ascorbic acid content of the blood on the course of the blood sugar curve. Acta Medical of Scotland 60; 255-265, 1992.


Studer RK, Craven PA, DeRubertis FR. Antioxidant inhibition of protein kinase C-signaled increases in transforming growth factor-beta in mesangial cells. Metabolism 46; 918-925, 1997.


West E, Simon OR, Morrison EY. Streptozotocin alters pancreatic beta-cell responsiveness to glucose within six hours of injection into rats. West Indian Med J 45; 60-62, 1996.


